Tag: migration

SANTA ANA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the presentation of a poster entitled, “Mechanism of Action of Troculeucel (Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) in Alzheimer's Disease Confirmed by Corresponding Phase I Biomarker Data” at the Alzheimer’s Association International Conference 2025 (“AAIC 2025”) held in Toronto, Canada and online from July 27-31, 2025.

Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the hidden dangers of cholesterol

Stage 2 Will Introduce Price Increase and APY Adjustment as Project Prepares for Solana Deployment and AI-Driven Governance Rollout

MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients

Rogers delivers strong results and completion of transformational investments in the second quarter

Critical infrastructure organisations face increased security, compatibility, performance, cost, and compliance risks if they delay upgrading to Windows 11.